Cabergoline vs MENT
FDA Approved vs Emerging
compatible Researched · 90% While MENT appears to have less progestogenic activity than nandrolone, some users report prolactin-related symptoms at higher doses. Cabergoline (0.25-0.5 mg twice weekly) can be used if bloodwork confirms elevated prolactin. Use only when indicated by symptoms or lab values, not prophylactically.
Molecular Data
Cabergoline MENT
Weight 451.60 Da 288.43 Da
Half-life ~63-69 hours ~40 minutes (acetate ester)
Type Ergoline-derived dopamine D2 receptor agonist 7-alpha-methyl-19-nortestosterone (C19H28O2)
Key Benefits
Cabergoline
01 Potent suppression of prolactin levels, often normalizing them within days
02 Prevents and reverses prolactin-related gynecomastia from 19-nor compounds
03 Restores sexual function impaired by hyperprolactinemia (libido, erectile function, orgasm)
04 Long half-life (63-69 hours) allows convenient twice-weekly dosing
05 Significantly better tolerated than bromocriptine with fewer gastrointestinal side effects
06 Effective at shrinking prolactin-secreting pituitary tumors
07 Low doses required for bodybuilding prolactin management (0.25-0.5mg twice weekly)
MENT
01 Approximately 10x more potent than testosterone, allowing effective results at very low doses (5-25 mg/day)
02 Does not cause the sexual dysfunction associated with other 19-nor compounds like nandrolone
03 Can potentially serve as a standalone base, replacing testosterone in hormone replacement protocols
04 Rapid clearance of the acetate ester allows quick dose adjustments and fast resolution of side effects upon discontinuation
05 Powerful lean mass accretion and strength gains relative to dose
06 Under investigation as a reversible male hormonal contraceptive
07 Resistance to 5-alpha reductase means it does not convert to DHT, potentially sparing hair follicles from direct DHT-mediated damage
08 Robust suppression of gonadotropins (LH/FSH), which is therapeutically useful in contraceptive applications
Dosing Protocols
Cabergoline
0.25-0.5mg twice weekly (bodybuilding); 0.5-1mg twice weekly (medical) / Twice weekly
MENT
5-25 mg/day (acetate) / Daily or split into 2x daily (acetate ester)
TRT Replacement - Low Dose 5-10 mg/day Daily (or split into 2 injections per day)
Moderate Anabolic Protocol 10-15 mg/day Split into 2 injections per day
Higher Dose - Advanced 15-25 mg/day Split into 2 injections per day
Side Effects
Cabergoline
Nausea (especially during initial doses; mitigated by taking with food)
Dizziness or lightheadedness
Headache
Nasal congestion or stuffiness
Fatigue or drowsiness
Orthostatic hypotension (feeling faint when standing up quickly)
MENT
Estrogen management difficulty -- 7-alpha-methyl-estradiol is harder to control with conventional aromatase inhibitors
Water retention and bloating, particularly at doses above 10 mg/day
Elevated blood pressure, often linked to water retention and estrogenic load
Mood changes including irritability, emotional sensitivity, or anxiety (frequently estrogen-related)
Profoundly suppressive of the HPG axis -- LH and FSH driven to near-zero even at low doses
Injection frequency burden (daily or twice-daily with acetate ester)
Mild acne and oily skin
Increased appetite
Contraindications
Known hypersensitivity to cabergoline or any ergot alkaloid
History of cardiac valvular disease or clinically significant valvular regurgitation
History of pulmonary, pericardial, or retroperitoneal fibrotic disorders
Uncontrolled hypertension
Concurrent use of dopamine antagonists (antipsychotics, antiemetics acting on D2 receptors)
Severe hepatic impairment (cabergoline is extensively metabolized by the liver)
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Breast cancer in males or females
Pregnancy or potential for pregnancy
Severe hepatic impairment
Polycythemia (hematocrit above 54% at baseline)
Uncontrolled hypertension or severe cardiovascular disease
Uncontrolled heart failure
Known hypersensitivity to trestolone or any formulation components
Research Evidence
Cabergoline MENT
Status FDA Approved Emerging
References 5 studies 5 studies
Latest — 2002
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.